EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Thyroid dysfunction in patients undergoing long-term amiodarone therapy

Mohsen Safari, Zeinab Safari, Muhammad Umar Soomro

Journal of Current Cardiology · 2026-01 · 4 (1) · 1-4

DOI: 10.4103/jcc.jcc_37_25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Current Cardiology, online erschienen am 11.03.2026. Verfasst von Mohsen Safari und 2 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amiodarone, a widely prescribed antiarrhythmic drug, is associated with significant thyroid dysfunction, including both hypothyroidism and hyperthyroidism. This systematic review and meta analysis aim to synthesize the available evidence on the prevalence, types, and management of amiodarone induced thyroid dysfunction (AITD) in patients on long term therapy. We conducted a systematic review and meta analysis of studies that examined thyroid dysfunction in patients receiving long term amiodarone therapy. A comprehensive search of PubMed, Google Scholar, and the Cochrane Library was performed, identifying studies published between 1990 and 2024. Eligible studies included prospective or retrospective cohort studies and randomized controlled trials (RCTs) reporting on the incidence of hypothyroidism, hyperthyroidism, and management strategies in this population. Twenty three studies, with a combined population of 12,000 patients, were included in the final analysis. The pooled incidence of hypothyroidism was 14.3% (95% confidence interval [CI]: 12.1%–16.9%, P < 0.001) and hyperthyroidism was 6.7% (95%CI: 5.1%–8.4%, P < 0.001). Geographical variation in incidence was noted, with higher rates of hyperthyroidism in iodine deficient regions. Amiodarone induced hypothyroidism was generally well managed with levothyroxine without discontinuing amiodarone. Amiodarone induced hyperthyroidism required either antithyroid drugs (for Type 1) or corticosteroids (for Type 2). Thyroid dysfunction, especially hypothyroidism, is common in patients receiving long term amiodarone therapy. Regular thyroid function monitoring is essential to manage this condition effectively. Further studies are needed to improve the management of amiodarone induced hyperthyroidism and optimize long term outcomes for these patients.

Zitieren

APA

Safari, M., Safari, Z., & Soomro, M. U. (2026). Thyroid dysfunction in patients undergoing long-term amiodarone therapy. Journal of Current Cardiology, 4(1), 1-4. https://doi.org/10.4103/jcc.jcc_37_25

Vancouver

Safari M, Safari Z, Soomro MU. Thyroid dysfunction in patients undergoing long-term amiodarone therapy. Journal of Current Cardiology. 2026;4(1):1-4. doi:10.4103/jcc.jcc_37_25

BibTeX
@article{Safari2026,
  author = {Safari, Mohsen and Safari, Zeinab and Soomro, Muhammad Umar},
  title = {Thyroid dysfunction in patients undergoing long-term amiodarone therapy},
  journal = {Journal of Current Cardiology},
  year = {2026},
  volume = {4},
  number = {1},
  pages = {1--4},
  doi = {10.4103/jcc.jcc_37_25}
}
Kostenlos starten →